MTFR2 and breast cancer: A previous study demonstrated that tumour grade, lymph node metastasis, HER2 status and other clinicopathological parameters are important in BC progression and metastasis and affect the prognosis of BC patients [23, 24] Furthermore, a Kaplan-Meier survival analysis indicated that the OS of patients with high levels of MTFR2 expression was significantly lower than that of patients with low levels of MTFR2 expression, and a Cox proportional analysis strongly indicated that MTFR2 might be useful as an independent prognostic marker for OS.